Results of 125-Iodine seed implant with preplanning system in 250 patients with prostate cancer - Abstract

Servicio de Oncología Radioterápica, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España.

 

We review the experience with prostate carcinoma patients treated with permanent implants of 125-I seeds and the outcome eight years after the beginning of this technique.

From 2002 to 2007 we have performed 250 implants with LDR brachytherapy with RapidStrand(®) and preplanning system. Mean age was 68 (49-78). Mean PSA was 7.32 (2.31 - 14.6). T1-T2a was the stage in 98%, and Gleason ≤ 6 in 96%. Low risk cases were 81% and intermediate risk 19% (ten of them received 46Gy EBRT). Hormonal treatment was used in 42%.

With a mean follow-up of 48 months, 14 patients (5.7%) showed biochemical failure (BF). Eleven patients (4.5%) with theoretical BF were observed and PSA decreased without treatment. Actuarial PSA relapse-free survival at 5 years was 91%, (92% low risk, 86% intermediate cases), and 92% vs 81% with PSA < 10 vs >10 (p< 0.05). Rectum complications were G2 in 0.6%. A urinary catheter was necessary in 6.5%. Sexual function was conserved in 60%. Mean V100 was 89% and D90 143Gy.

The outcome of patients with low risk prostate carcinoma treated with I-125 seed is very good with very low complications rate. Cases with PSA bounces should be controlled before starting a salvage treatment.

Article in English, Spanish.

Written by:
Guinot JL, Ricós JV, Gimeno J, Tortajada MI, Carrascosa M, Santos M, Casanova J, Soler P, Crispín V, Arribas L.   Are you the author?

Reference: Actas Urol Esp. 2011 Apr 7. Epub ahead of print.
doi: 10.1016/j.acuro.2011.02.003

PubMed Abstract
PMID: 21481974

UroToday.com Prostate Cancer Section

 

 

email news signup